Abstract: Montelukast, a leukotriene receptor antagonist, was marketed in 1998 as an oral supplementary treatment to patients with mild to moderate asthma. The aim of this study was to describe the early discontinuation pattern among montelukast users in Denmark in the period of 1 March 1998 to 31 December 2016, and to identify demographic characteristics possibly associated with early discontinuation. This nationwide drug utilization study was based on data collected from three nationwide Danish registers. All montelukast users who redeemed at least one prescription in the study period were identified. Early discontinuation was defined as failing to fill a second prescription for montelukast within at least a year after the initial montelukast prescription. Among 135,271 included montelukast users, 47,480 (35%) discontinued the use of montelukast after a single redeemed prescription. The trend in early discontinuation increased throughout the years. The most predominant demographic risk factors for early discontinuation were prescription for only nasal topical anti-allergic treatment up to a year prior to montelukast initiation [adjusted odds ratio (OR) 2.25; 95% confidence interval (CI) 2.13-2.38], as well as suspected off-label use (adjusted OR 2.02; 95% CI 1.97-2.08). Several risk factors were associated with a decreased risk of early discontinuation; most pronounced was a prescription of inhaled corticosteroids within a year up to montelukast initiation [adjusted OR 0.47 (95% CI 0.46-0.49)]. Early discontinuation was more pronounced after patent expiry in 2012 [adjusted OR 1.42 (95% CI 1.38-1.45)]. In conclusion, we found that early montelukast discontinuation increased during the last 19 years. Appropriateness of the treatment indication as estimated by concomitant prescription of adequate inhalation therapy was associated with a low risk of early discontinuation. A more pronounced early discontinuation was observed after patent expiry in 2012, which could reflect a more liberal approach to montelukast prescription.
Asthma is a complex respiratory disease involving several cell types and mediators [1] . The disease affects approximately 315 million individuals of all ages worldwide [2] . The prevalence of asthma is increasing and predominantly common in the industrialized countries with significant high morbidity, mortality and increasing global economic burden [3, 4] . Asthma is also associated with several other diseases, for example allergic rhinitis (AR). In AR, 80% have some degree of rhinitis, but in non-allergic asthma most cases of rhinitis are non-allergic. In the ARIA report, it is stated that nasal symptoms are reported in 6-85% of asthmatic patients [5] .
Due to the increasing global burden of asthma, a set of international guidelines have been produced to approach a standardized optimal assessment and treatment of asthma [6] . The goal is to relieve asthmatic symptoms, prevent exacerbations and improve the quality of life (QoL). The current strategy paper for asthma treatment by the Global Initiative for Asthma (GINA) recommends inhaled corticosteroids (ICS) as first-line treatment. However, asthma is often inadequately controlled [7] warranting add-on therapies for mild, moderate and severe asthma symptoms (GINA steps 2 and 3). Accordingly, a long-acting b2-agonist (LABA) is commonly added if asthma is not controlled with ICS alone [8, 9] . In patients who experience intolerable side effects from ICS, or continue to have an uncontrolled asthma despite treatment with a combination of ICS and LABAs, treatment with montelukast is recommended [10, 11] .
Montelukast is a potent leukotriene receptor antagonist that specifically binds to the cysteinyl leukotriene receptor type 1, thereby blocking the action of leukotriene D4. Several studies have shown significant improvements in both symptoms and QoL for asthmatic patients when treated with montelukast as either monotherapy or in combination with ICS or combination of ICS and LABAs [12] [13] [14] [15] [16] [17] . Montelukast was introduced to the market in 1998 under the trademark name Singulair â and was covered by the US patent until 3 August 2012 when the patent expired. It has undergone a major price reduction since the patent expiry as several generic brands were approved. Montelukast is generally considered safe and tolerable [18] . The most common side effects are headache, abdominal pain and diarrhoea [19] , which might lead to discontinuation of the montelukast treatment [20, 21] . We have recently shown that almost half of all patients initiating montelukast discontinue their treatment after 2 months, and only a third of all patients are still in treatment after 12 months [22] . To improve a rational treatment approach, it is important to identify patients who may discontinue treatment. No study has yet identified this patient population.
Consequently, the aim of this study was to ascertain whether early montelukast discontinuation was due to off-label Author for correspondence: Daniel P. Henriksen, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, J.B. Winsløws Vej 19, 2., 5000 Odense, Denmark (e-mail dphenriksen@ health.sdu.dk).
use and increased availability since its patent expiry in 2012 and to identify demographic characteristics possibly associated with early discontinuation.
Materials and Methods
In this nationwide follow-up study of Danish citizens initiating montelukast treatment, we described early discontinuation. We obtained prescription data for all montelukast users in Denmark during the study period of 1 March 1998 to 31 December 2016.
Data sources. We obtained data from three different nationwide data sources: the Danish National Patient Register (DNPR), The Register of Medicinal Products Statistics (RMPS) and the Danish Civil Person Register (DCPR). The DNPR is a nationwide hospital registry that has collected data on secondary care in Denmark since 1977 [23] . The registry collects data on all patients admitted to a hospital, outpatient contacts and emergency room contacts. The register contains information about discharge diagnoses, dates of admission and discharge as well as procedure codes. The discharge diagnoses are based on the International Classification of Diseases (ICD); the ICD-8 version was used until 1993 and ICD-10 from 1994 [24] .
The RMPS has been available to all researchers in Denmark since 2003. The RMPS contains complete information on all prescriptions and reimbursable drugs redeemed by Danish citizens at outpatient pharmacies since 1995. The data do not contain information about drugs administered in hospital settings or as over-the-counter drugs. The RMPS includes different variables, which include information about the dispensed drugs, the prescriber and information about the patient. Information about the dispensed drug includes type of drug, quantity, name, date of dispensing, dosage and strength of the drug. The dispensed drug includes the Anatomic Therapeutic Chemical (ATC), which is a classification code developed by WHO and as well the defined daily dose (DDD) [25] .
The DCPR contains information about all residents' migration in and out of Denmark and their vital and civil status [26] . It is possible to conduct true population-based register linkage studies covering the entire population due to the unique civil registration number, given to all Danish citizens at birth, as well as the fact that the Danish healthcare system provides tax-supported health care for the entire Danish population. [26] .
Study drug. In this study, we included all montelukast users within the ATC (ATC, R03DC03) who redeemed at least one prescription for montelukast in the study period of 1 March 1998 to 31 December 2016. Patients were followed until death, emigration or as of 31 December 2016 as end of the study period. The DDD of montelukast is 10 mg according to the WHO [25] . We defined early discontinuation as montelukast users who failed to fill a second prescription for montelukast within at least 1 year after their initial montelukast prescription. We excluded patients with a follow-up period of less than 1 year in accordance with our definition of early discontinuation.
Definitions. We used discharge diagnoses since 1994 to compute a Charlson comorbidity score, as proposed by Charlson et al., to form the Charlson Comorbidity Index (CCI) for all patients included in the study. This serves as a surrogate marker of comorbid illness and is a weighted score. We defined four levels of comorbidity burden, from low to severe (CCI 0-3+).
We defined an asthma-related admission as a primary discharge diagnosis of asthma (ICD10 J44.8B, J45, J46), within a year prior to montelukast initiation, and chronic obstructive pulmonary disease (COPD)-related admission was defined as a primary discharge diagnosis of COPD (J44 excluding J44.8B).
We defined use of selected medicines in two ways. Usage was defined as a redeemed prescription of the medicine within a year prior to montelukast initiation: (1) stratified by selected combinations; (2) based on the active substance (i.e. ICS, where we included both ICS fixed dose and LABA + ICS combinations). Systemic antihistamines and nasal topical anti-allergic treatment were defined as a redeemed prescription up to a year prior to montelukast initiation of ATC R06A (systemic antihistamines) or R03AC/R03AD (nasal topical anti-allergic treatment).
Suspected off-label use was defined as no redeemed prescription of ICS, systemic antihistamines, or nasal topical anti-allergic treatment within a year prior to montelukast initiation.
Analysis. We presented baseline characteristics of users who did and did not discontinue montelukast early as absolute numbers and percentages for categorical variables, and medians with interquartile ranges (IQR) for continuous variables. The main outcome was the proportion of early discontinuation. We computed figures presenting the proportion of early discontinuation by calendar year stratified by age, comorbidity and suspected off-label use.
Using logistic regression analysis, we computed the odds ratios for the association of demographic risk factors and early discontinuation of montelukast in two models: a crude model and an adjusted model where we adjusted for the predefined clinical relevant confounders: age, sex, comorbidity and suspected off-label use.
Lastly, we assessed whether patients were more likely to discontinue montelukast after the patent expired in 2012. We used a chi-square as a significance test and assessed whether it was an independent risk factor using logistic regression, adjusting for the covariates mentioned above.
Results
We identified a total of 147,247 montelukast users in Denmark during the study period of 1 March 1998 to 31 December 2016. During the 19-year study period, a total of 1,327,489 montelukast prescriptions were filled. We included 135,271 (91.9%) persons redeeming one or more prescriptions for montelukast within the period and with at least 1 year of follow-up. A total of 47,480 (35.1%) users discontinued montelukast treatment early.
The baseline characteristics of the montelukast users are given in table 1. The median age of the patients was 34 years (IQR: 10-55) for the patients who discontinued montelukast treatment early and 36 years (IQR: 9-58) for the patients who redeemed more than one prescription for montelukast.
Additional analyses of trends in early discontinuation stratified by age ( fig. 1) , CCI, and suspected on-label use (Supplementary Appendix 1) all showed an increasing proportion of early discontinuation throughout the study period.
A total of 98,830 patients initiated montelukast before 2012, and of those, 32,272 (32.7%) were early discontinuers, whereas among the 36,441 patients who initiated montelukast from 2012 to 2016, 15,208 (41.7%) were early discontinuers (p < 0.001). We found that redeeming a prescription for montelukast after the patent expiry was associated with early discontinuation (n = 9218), p < 0.001]. The largest proportion of suspected off-label use was observed among patients aged 0-17 years (28.7%, n = 14,352), whereas the lowest proportion was among patients aged 40-64 years (13.6%, n = 5302).
Discussion
This is the first study to report an analysis of nationwide early discontinuation trends of montelukast, a LTRA used for the treatment of asthma and seasonal AR in Denmark. Using nationwide register-based prescription data, we showed an increasing proportion of early discontinuation during the study period.
We found that a prescription for nasal topical anti-allergic treatment alone within a year prior to montelukast initiation, as well as suspected off-label use of montelukast (i.e. no prescription of ICS, systemic antihistamines, or nasal topical antiallergic medicine within a year prior to montelukast initiation), was the most predominant risk factor for early discontinuation. Increasing comorbidity, a recent asthma-, or COPD-related admission, as well as the use of long-acting inhalation therapy (ICS, LAMA or LABA), were all associated with a decreased risk of early discontinuation.
The main strength of the present study is the inclusion of a substantial number (>135,000) of montelukast users from a validated nationwide prescription register. During our study period, we had access to several national registers through the unique personal identification number allocated to all Danish residents. We used complete and valid information on montelukast dispensed to the Danish population during a period of 19 years with complete and comprehensive health coverage through the DNPR. Data are systemically and electronically collected, regardless of insurance-or socio-economic status. A general limitation to prescription register-based studies is using prescriptions as a proxy of exposure. We recorded redeemed prescriptions and not actually administered doses, which made it impossible to quantify the severity of disease. Only lowand moderate-dose ICS are marketed in Denmark; thus, we could not identify whether the patient was in high-dose ICS treatment. This might have contributed to an overestimation of drug use. It would have been interesting to assess whether asthma severity is associated with a decreased or increased discontinuation. We could not account for neither treatment during hospitalization nor drugs used in institutions, as these are not covered by the register. This information might underestimate the proportion of exact drug use but is unlikely to substantially impact our results.
There are several other studies on early discontinuation among patients with different chronic diseases. A study from the UK, using the primary care database, found that 28% discontinued antidepressants after their first prescription. Of those, 8.6% restarted after a month off-treatment and 24.1% after 9 months [27] . In patients who initiated medication for ADHD, 12.6% failed to fill a second prescription within 6 months [28] . The duration of proton pump inhibitor therapy has been shown to depend heavily on age. Only 15% of patients aged 18-39 years are still in treatment after 3 months, whereas 50% of patients aged 80-89 years are still in treatment after 3 months. This shows a wide range of discontinuation depending on the treatment and disease [29] . Discontinuation likely reflects the efficacy and adverse effects of the studied medication, patient preferences as well as the severity of the underlying disease.
We showed that the risk of early discontinuation among children and adolescents below 18 years of age was lower compared to all other age groups. A potential explanation could be poor compliance and adherence towards the inhalation therapy and fear of potential side effect to ICS. Such has been described among children and adolescents [30] [31] [32] . Oral therapy might be preferable as the administration route of montelukast; such is easy and inconspicuous, and compliance is supported. Improved compliance of leukotriene antagonist therapy among adolescents, when using once-daily orally administered montelukast compared to inhalation therapy has previously been documented [33, 34] . Similarly, for elderly patients above 65 years of age, a possible explanation of their higher risk of discontinuation pattern could be non-adherence towards inhalation therapy [18, 35] . Efficacy and effectiveness of montelukast in the elderly is less well substantiated and may explain an increased tendency to discontinue treatment in this population. A small placebo-controlled, randomised study among 25 patients with asthma treated with montelukast showed no effect on asthma symptoms, spirometry values, peripheral blood eosinophils or IgE [36] . However, the results should be interpreted with caution due to the small number of included patients.
A study showed that the patients in the age group of 18-39 years had lower rates of compliance [37] and hence a higher rate of early discontinuation. Another possible explanation of the increased early discontinuation in this age group could be better asthma control, mitigating the need for montelukast add-on therapy. Surprisingly, we found that the suspected off-label use was most pronounced among patients aged 0-17 years (28.7%), whereas the lowest proportion was among patients aged 40-64 years (13.6%). This weakens the argument that off-label use solely could explain early discontinuation in the various age groups.
We found that off-label use was the most predominant independent risk factor for early discontinuation. This is a reassuring observation. It is legal to prescribe medication offlabel, but the efficacy is less established. Several off-label studies have shown only a modest benefit in diseases like eosinophilic oesophagitis [38] , or for secondary prevention of cardiovascular disease, among others [39] . However, in the current study, it was not possible to identify the indication for which montelukast has been prescribed. It appears that appropriate indications for initiation of therapy are related to a continuous user profile.
Generally, the effectiveness of montelukast varies substantially from the patients' perspective. A cross-sectional study from 2005 found that 66% among 1351 patients reported improvement in their asthma control, whereas only 9% reported dramatic improvement [40] . Asthma is a complex disease, expressing a large degree of disease and response heterogeneity [41] , and early discontinuation may be related to clinical efficacy of montelukast within specific asthma phenoor genotypes [1] . Early discontinuation could also be due to adverse drug reactions (ADR). A literature review of published case reports on montelukast-induced ADR described a broad spectrum of individually reported ADRs including immune system reactions, such as hepatic infiltration and autoimmune vasculitis (Churg-Strauss syndrome), various psychiatric disorders, dream disturbances and hallucinations [42] . Despite this, montelukast is perceived and characterized as a relatively safe and well-tolerated drug [43, 44] . Thus, discontinuation could be due to a positive behaviour, avoiding unnecessary treatment due to lack of efficacy, or negative behaviour due to misunderstanding, adverse effects or noncompliance. To assess this, it would be interesting to conduct a clinical questionnaire or a qualitative interview with early discontinuers to gain more knowledge on why they discontinued montelukast after a single prescription. It is difficult to assess the clinical importance of the increased proportion of montelukast discontinuation. Patients who discontinue montelukast could perhaps also be patients who have difficulties in maintaining their inhalation therapy. We have not accounted for this in the present study but it would be interesting to assess in a future study.
Montelukast is indicated in mild to moderate asthma as a supplement treatment, which could explain the increased proportion of early discontinuers. The clinical approach, in daily practice, was to consider the possible impact of montelukast after 10-14 days and to discontinue if the patient did not experience an effect of the treatment, or if the patient experienced adverse events that exceeded the effect. It seems that the discontinuation could be due to rational patient behaviour balancing improved asthma control against adverse effects, price and convenience. This is in line with the finding of qualitative studies on other treatments, where ownership, knowledge and support were important factors for patient adherence [45] .
We found a significantly larger proportion of patients who were early discontinuers after the patent expired in 2012. Using logistic regression analysis, we found an adjusted OR 1.42 for early discontinuation in the period of 2012-2016 compared to the period of 1998-2011. This could indicate a more liberal approach to montelukast prescription that may relate to substantial price reductions upon introduction of generic products. This theory is supported by the observation of a significantly increased proportion of suspected off-label use in the post-patent expiry period.
In conclusion, early montelukast discontinuation has increased during the last 19 years. Appropriateness of the treatment indication as estimated by concomitant prescription of adequate inhalation was associated with a low risk of early discontinuation. A pronounced early discontinuation was observed after the patent expiry in 2012, which could indicate a more liberal approach to montelukast prescription.
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